Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib.

CONCLUSION: CABO monotherapy appears to be safe and effective as a monotherapy in advanced ACC after failing prior treatments. Therefore, prospective investigation of CABO in ACC patients is warranted.
PMID: 31900481 [PubMed - as supplied by publisher]

Source: The Journal of Clinical Endocrinology and Metabolism - January 3, 2020 Category: Endocrinology Authors: Kroiss M, Megerle F, Kurlbaum M, Zimmermann S, Wendler J, Jimenez C, Lapa C, Quinkler M, Scherf-Clavel O, Habra MA, Fassnacht M Tags: J Clin Endocrinol Metab Source Type: research